About Goldencross Pharma Limited
Data last updated:
Goldencross Pharma Limited is a public limited company based in Mumbai, Maharashtra, India, a subsidiary of Cipla Limited. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 21 January 2000 and has been in existence for over 26 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24239MH2000PLC123766. Its GSTIN is 02AABCG0541J1Z6 (Himachal Pradesh). The company holds 4 GST registrations, all of them active.
The company has an authorised share capital of ₹4 Cr and a paid-up capital of ₹4.6 Lakh. It was formerly known as Goldencross Pharma Private Limited. It is led by directors including Ujjwal Prakash Shendre (Managing Director) and Anisha Naresh Udeshi.
Its last annual general meeting (AGM) was held on 25 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Tower A 1st Floor Peninsula Business Park Ganpatrao Kadam Marg Lower Parel, Mumbai, Maharashtra, India – 400013.
As per the financials filed for FY 2025, the company reported a revenue of ₹187.87 Cr, a growth of 31% compared to the previous year. For the same year it recorded a net profit of ₹18.74 Cr (net margin 10%) and EBITDA of ₹29.64 Cr (EBITDA margin 15.8%). Revenue has grown at a compounded annual rate (CAGR) of 11% over three years and 3% over five years.
The company has about 322 employees on its provident fund (EPFO) records.
As per MCA filings, the company has satisfied charges of ₹91.5 Cr on record. Court records list 3 cases involving the company, including 2 filed by the company and 1 filed against it. The company has 5 deals on record (2 funding rounds, 2 secondary share transfers, 1 acquisition), with disclosed funding of ₹2.95 Cr; the latest was in June 2010. Its 7 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 4 smaller; the largest is Sriram Healthcare Private Limited with revenue of ₹192.28 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website cipla.com.
Company details
CIN history
Goldencross Pharma has one previous CIN (Corporate Identification Number): U24239MH2000PTC123766. The current CIN is U24239MH2000PLC123766, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24239MH2000PLC123766 | Current |
| U24239MH2000PTC123766 | Previous |
Contact details
Goldencross Pharma Limited's registered office is in Mumbai, Maharashtra. Its website is cipla.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressTower A 1st Floor Peninsula Business Park Ganpatrao Kadam Marg Lower Parel, Mumbai, Maharashtra, India – 400013
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Goldencross Pharma Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Goldencross Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Goldencross Pharma Limited, buy the company report.
Financials of Goldencross Pharma Limited
FY 2025 filings availableGoldencross Pharma Limited reported revenue of ₹187.87 Cr (up 31% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 3% over five years, including 31% growth in the latest year. EBITDA rose 17% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹29.64 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹18.74 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 15.8% | ||||
| Net Profit Margin | 10% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Goldencross Pharma Limited, buy the company report.
Board of directors of Goldencross Pharma Limited
Goldencross Pharma has 4 current directors and 21 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Anisha Naresh Udeshi | Director | 08 Jun 2020 | 6 Years 5 Months | Current |
| Swapn Bhawani Malpani | Director | 16 Dec 2024 | 1 Years 10 Months | Current |
| Ujjwal Prakash Shendre | Managing Director | 24 May 2023 | 3 Years 5 Months | Current |
| Rajendra Kumar Chopra Also directs: Meditab Specialities Limited, Cipla Pharma and Life Sciences Limited, Cipla Pharmaceuticals Limited and 3 more | Director | 03 Jan 2019 | 7 Years 10 Months | Current |
Peer comparison
Goldencross Pharma Limited is compared with the 7 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Sriram Healthcare Private Limited | ₹192.28 Cr (FY 2025) | -8.0% | Kasauli, Himachal Pradesh, India | |||
| Parnax Lab Limited | ₹189.41 Cr (FY 2025) | 0.0% | Mumbai, Maharashtra, India | |||
| Regenix Drugs Limited | ₹188.37 Cr (FY 2024) | 9.0% | Chennai, Tamil Nadu, India | |||
| Goldencross Pharma Limitedthis company | ₹187.87 Cr (FY 2025) | ₹18.74 Cr | 10% | 31.0% | Mumbai, Maharashtra, India | |
| Comed Chemicals Limited | ₹187.35 Cr (FY 2025) | 12.0% | Vadodara, Gujarat, India | |||
| Mapra Laboratories Pvt Ltd | ₹184.45 Cr (FY 2025) | 5.0% | Mumbai, Maharashtra, India | |||
| Naxpar Pharma Private Limited | ₹183.89 Cr (FY 2025) | 1.0% | Mumbai, Maharashtra, India | |||
| Infutec Healthcare Limited | ₹183.11 Cr (FY 2021) | -22.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Goldencross Pharma Limited, buy the company report.
Auditor
Goldencross Pharma Limited is audited by Walker Chandiok & Co LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Walker Chandiok & Co LLP | FY 2023 | 001076N/N500013 |
Shareholding
The shareholding of Goldencross Pharma Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Goldencross Pharma Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 03 Feb 2009 | 10142776 | The Hongkong and Shanghai Banking Corporation Limited | ₹90 Cr | Satisfied | |
| 18 Mar 2002 | 90237480 | Credit Lyonnias | ₹75 Lakh | Satisfied | |
| 08 Mar 2002 | 90237477 | Credit Lyonnias | ₹75 Lakh | Satisfied |
To see the full charge records of Goldencross Pharma Limited, buy the company report.
Total charge records: 3 View all charges
Deals & funding
Goldencross Pharma Limited has 5 deals on record (2 funding rounds, 2 secondary share transfers, 1 acquisition), with disclosed funding of ₹2.95 Cr; the latest was in June 2010.
Deals on record (5 of 5)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jun 2010 | Acquisition | ₹139.61 Cr | Buyer: Cipla Limited |
| May 2010 | Secondary share transfer | Undisclosed | Buyer: Cipla Limited & S. Radhakrishnan, Sanghvia A Mital Jtly Cipla Limited, Cipla Limited Seller: MN Rajkumar Garments LLP , Shree Riddhi Chemicals Pvt Ltd , 2 individuals |
| Mar 2010 | Funding round | ₹90.5 Lakh | Investors: Good Earth Remedies Limited , Globus Healthcare Limited |
| Sep 2007 | Secondary share transfer | Undisclosed | Buyer: Respair Technologies India Private Limited Seller: Premratan Exports Pvt Ltd |
| Jun 2007 | Funding round | ₹2.04 Cr | Investors: Pam Remedies Private Limited , 3 individuals |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Goldencross Pharma Limited has 3 court cases on record: 2 filed by Goldencross Pharma, 1 filed against it. All cases are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 2 | 0 | 0 |
| High courts | 1 | 1 | 0 |
Cases on record (3 of 3)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Gangtok, Sikkim | Civil suit | Filed by the company against individuals | Disposed |
| District court, PAKYONG, Sikkim | Civil suit | Filed by the company against an individual | Disposed |
| Bombay High Court | Court case (NMA) | Filed against the company by The Commissioner of Income-Tax- City VI Mumbai | Disposed |
To see the full case history of Goldencross Pharma Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Goldencross Pharma Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Goldencross Pharma has 4 GST registrations: 4 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 02AABCG0541J1Z6 | Himachal Pradesh | Active | 01 Jul 2017 |
| 11AABCG0541J1Z7 | Sikkim | Active | 01 Jul 2017 |
| 24AABCG0541J1Z0 | Gujarat | Active | 01 Jul 2017 |
| 30AABCG0541J1Z7 | Goa | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Goldencross Pharma Limited, buy the company report.
Recent activity
Goldencross Pharma Limited has 23 board changes on record since 2007: 4 appointments and 19 cessations. The latest: Swapn Bhawani Malpani ceased to be Additional Director on 24 Sep 2025.
21 earlier events are in the company report.
News
Frequently asked questions
Goldencross Pharma is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 21 January 2000 (26+ years old) and is registered under CIN U24239MH2000PLC123766.
Goldencross Pharma has 4 current directors:
- Ujjwal Prakash Shendre - Managing Director
- Anisha Naresh Udeshi - Director
- Swapn Bhawani Malpani - Director
- Rajendra Kumar Chopra - Director
The latest financial statements of Goldencross Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 25 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Goldencross Pharma is 02AABCG0541J1Z6, registered in Himachal Pradesh. The company has 4 GST registrations in all, of which 4 are active. Other active GSTINs include 11AABCG0541J1Z7 (Sikkim), 24AABCG0541J1Z0 (Gujarat), 30AABCG0541J1Z7 (Goa).
The CIN (Corporate Identification Number) of Goldencross Pharma is U24239MH2000PLC123766. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Goldencross Pharma has 3 court cases on record: 2 filed by the company and 1 filed against it. Most are in the district courts.
Goldencross Pharma was incorporated on 21 January 2000, making it 26+ years old. It is registered with the Registrar of Companies, Mumbai.
Goldencross Pharma has 5 deals on record (2 funding rounds, 2 secondary share transfers, 1 acquisition), with disclosed funding of ₹2.95 Cr; the latest was in June 2010.
The peers of Goldencross Pharma by revenue are Sriram Healthcare Private Limited, Parnax Lab Limited, Regenix Drugs Limited, Comed Chemicals Limited, Mapra Laboratories Pvt Ltd and 2 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Swapn Bhawani Malpani ceased to be Additional Director on 24 Sep 2025. Swapn Bhawani Malpani was appointed as Director on 16 Dec 2024. Ujjwal Prakash Shendre was appointed as Managing Director on 24 May 2023. Goldencross Pharma has 23 board changes on record in total.
Goldencross Pharma can be reached through the website cipla.com. Its registered office is in Mumbai, Maharashtra, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
